BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

August 31, 2026

From BeOne Medicines, Ltd.

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

Performance

52-Week Range 4.5% below 52-week high

368.04

253.9552W Low 385.2252W High

1 Week 2.0% below 1-week high

344.941W Low 375.641W High

BeOne Medicines Ltd. - American Depositary Shares (ONC) traded between $253.95 and $385.22 over the past 52 weeks and last traded at $368.04, 4.5% below its 52-week high. Over the past week it ranged between $344.94 and $375.64.

Past 12 Months

+3.8%

+6.2%

+15.9%

+14.8%

+18.3%

+16.4%

1W +$13.56

1M +$21.54

3M +$50.62

6M +$47.34

YTD +$57.02

1Y +$51.89

ONC was +16.4% over the past year, +14.8% over six months, +18.3% year to date, +3.8% in the last week.

12 Months vs Market

ONC

+16.4%

DIA

+13.4%

SPY

+16.0%

QQQ

+19.6%

IWM

+9.9%

Over the past 12 months ONC returned +16.4% versus DIA (Dow) +13.4%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +19.6% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 0.28× 3-mo avg

Today 108,467 3-mo avg 391.2K

394.3K

379.6K

391.2K

333.9K

YTD

309.3K

302.0K

ONC most recently traded 108,467 shares against a 3-month average daily volume of 391.2K.

More News

August 31, 2026

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

August 25, 2026

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

August 18, 2026

BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

August 10, 2026

BeOne Medicines Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

August 05, 2026

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

July 23, 2026

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗

July 22, 2026

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

July 17, 2026

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

June 30, 2026

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

June 12, 2026

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

June 11, 2026

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗

June 02, 2026

Via MarketBeat

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

June 01, 2026

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

May 29, 2026

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

May 27, 2026

BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

May 21, 2026

BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard

May 20, 2026

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026